Rani Therapeutics Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.6M | $1.0M | $0 | $0 | $2.7M |
| Operating income | -$38.3M | -$53.3M | -$66.1M | -$63.5M | -$51.6M |
| Operating expenses | $39.9M | $54.3M | $66.1M | $63.5M | $54.3M |
| Cash from operations | -$18.7M | -$35.5M | -$51.2M | -$46.5M | -$32.2M |
| Capital expenditure | $88,000 | $268,000 | $1.2M | $1.6M | $506,000 |
| Free cash flow | -$18.8M | -$35.8M | -$52.5M | -$48.1M | -$32.8M |
| Impairments | $0 | $3.7M | $0 | — | — |
| Total assets | $58.6M | $36.6M | $57.9M | $108.0M | $124.2M |
| Total liabilities | $17.1M | $33.1M | $32.5M | $34.0M | $2.6M |
| Total debt | — | $24.6M | $29.4M | $29.1M | $0 |
Shares outstanding 123.9M · Free float 36.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.